Caregiver-reported emotional-behavioral symptoms in Spanish youth during the COVID-19 pandemic: a longitudinal study.

BACKGROUND: COVID-19 pandemic stressors affected youth's mental health. This longitudinal study aims to explore these effects while considering predictive factors such as age and sex. METHODS: An initial sample of 1502 caregivers answered a longitudinal survey evaluating their youths' (4-17 years of age) emotional/behavioral symptoms using the Pediatric Symptom Checklist (PSC) screening tool. First assessment in May-July 2020 included the prior year's retrospective (TR) and since-lockdown-start (T0) PSC, followed by monthly evaluations until February 2021. RESULTS: A positive screening PSC (PSC+) was reported in 13.09% of cases at TR and 35.01% at T0, but the likelihood of PSC+ quickly decreased over time. At T0, a more pronounced impact was found on children (39.7%) compared to adolescents (25.4%); male children exhibited higher risk for a PSC+ at T0 and longitudinally than females. Adolescents presented a weaker effect of time-improvement. PSC+ at TR, experienced stressors, and caregiver's stress/depressive symptoms positively predicted PSC+ at T0 and longitudinally; adolescents' unproductive coping style predicted PSC+ at T0. CONCLUSION: The study shows a caregiver-reported increase in emotional/behavioral symptoms in youths during the COVID-19 pandemic, affecting predominantly younger children in the early stages and showing gradual improvement over time, albeit possibly slower in adolescents. IMPACT: The results show the anticipated surge in emotional and behavioral symptoms during the COVID-19 lockdown in youth reported by caregivers, followed by subsequent amelioration. Of greater significance, the study reveals a heightened impact on young children initially, yet it suggests a slower improvement trajectory in adolescents. The study also identifies risk factors linked to emotional and behavioral symptoms within each age group. Alongside the longitudinal approach, the authors underscore the remarkable inclusion of a significant representation of young children, an unusual feature in such surveys.

Metadona para el tratamiento de la dependencia de opioides de prescripción médica. Una revisión retrospectiva de historias clínicas / Methadone for the treatment of Prescription Opioids Dependence. A retrospective chart review

La adicción a opioides de prescripción médica (OPM) está incrementado a niveles epidémicos. Los pocos estudios que existen hasta la fecha sobre su tratamiento se basan principalmente en el uso de buprenorfina. Sin embargo, la metadona puede considerarse como otra opción. El objetivo de nuestro estudio fue revisar las historias clínicas de todos los pacientes ingresados en una unidad de psiquiatría para la desintoxicación de OPM usando metadona entre el 2010 y el 2013. El periodo de evaluación finaliza a los 3 meses desde el alta médico. Pese a ser una revisión de historia clínicas, se evaluaron las características sociodemográficas de la muestra, así como las variables relacionadas con el tratamiento y la tasa de abstinencia durante el estudio. Se incluyeron 11 pacientes, mayoritariamente mujeres (81,8%), con una mediana de edad de 50 años. La mediana de duración de la dependencia fue de 8 años. Hubo una alta prevalencia de adicción a otras sustancias así como de comorbilidades psiquiátricas. Ocho pacientes fueron seguidos durante al menos 3 meses. De estos, 7 (87,5%) estuvieron abstinentes hasta el final del periodo evaluado por el estudio. Los resultados sugieren la necesidad de estudios de mayor rigor metodológico para la correcta evaluación de la metadona como un tratamiento potencialmente eficaz para la dependencia de los OPM

Prescription opioids (PO) addiction is increasing to an epidemic level. Few studies exist regarding its treatment. Although buprenorphine has been the mainstay so far, other treatment options might be considered, such as methadone. We conducted a retrospective assessment of all patients admitted to a psychiatry ward for PO detoxification using methadone between 2010 and 2013. The assessment and description was carried out during a 3-month follow-up period after their discharge. Although this is a retrospective chart review, our exploration included sociodemographic and treatment variables in addition to the abstinence rates for the whole sample. Eleven patients were included, mostly women (81.8%), with a median age of 50 years. The median duration of dependence was 8 years. Dependence on other substances and psychiatric comorbidities were high. Eight patients were monitored during three months. Of these, 7 (87.5%) were abstinent after that period. The results suggest that methadone deserves further exploration as a potentially efficacious treatment option for PO dependence

Methadone for the treatment of Prescription Opioids Dependence. A retrospective chart review. / Metadona para el tratamiento de la dependencia de opioides de prescripción médica. Una revisión retrospectiva de historias clínicas.

Prescription opioids (PO) addiction is increasing to an epidemic level. Few studies exist regarding its treatment. Although buprenorphine has been the mainstay so far, other treatment options might be considered, such as methadone. We conducted a retrospective assessment of all patients admitted to a psychiatry ward for PO detoxification using methadone between 2010 and 2013. The assessment and description was carried out during a 3-month follow-up period after their discharge. Although this is a retrospective chart review, our exploration included sociodemographic and treatment variables in addition to the abstinence rates for the whole sample. Eleven patients were included, mostly women (81.8%), with a median age of 50 years. The median duration of dependence was 8 years. Dependence on other substances and psychiatric comorbidities were high. Eight patients were monitored during three months. Of these, 7 (87.5%) were abstinent after that period. The results suggest that methadone deserves further exploration as a potentially efficacious treatment option for PO dependence.

La adicción a opioides de prescripción médica (OPM) está ahasta la fecha sobre su tratamiento se basan principalmente en el uso de buprenorfina. Sin embargo, la metadona puede considerarse como otra opción. El objetivo de nuestro estudio fue revisar las historias clínicas de todos los pacientes ingresados en una unidad de psiquiatría para la desintoxicación de OPM usando metadona entre el 2010 y el 2013. El periodo de evaluación finaliza a los 3 meses desde el alta médico. Pese a ser una revisión de historia clínicas, se evaluaron las características sociodemográficas de la muestra, así como las variables relacionadas con el tratamiento y la tasa de abstinencia durante el estudio. Se incluyeron 11 pacientes, mayoritariamente mujeres (81,8%), con una mediana de edad de 50 años. La mediana de duración de la dependencia fue de 8 años. Hubo una alta prevalencia de adicción a otras sustancias así como de comorbilidades psiquiátricas. Ocho pacientes fueron seguidos durante al menos 3 meses. De estos, 7 (87,5%) estuvieron abstinentes hasta el final del periodo evaluado por el estudio. Los resultados sugieren la necesidad de estudios de mayor rigor metodológico para la correcta evaluación de la metadona como un tratamiento potencialmente eficaz para la dependencia de los OPM.

Two cases of long-acting paliperidone in adolescence.

Paliperidone palmitate long-acting injection (PPLAI) is an atypical antipsychotic agent currently approved by the European Medicine Agency for the acute and maintenance treatment of schizophrenia in adults. However, there is no information so far on safety and effectiveness in patients under 18 years of age. We report on two clinical cases of adolescents with a psychotic spectrum disorder treated with PPLAI in an inpatient setting. The cases illustrate that PPLAI may hold potential as an effective and acceptably tolerated antipsychotic drug in adolescents with psychotic spectrum disorders. Given the lack of approved long acting injectable antipsychotics in patients under 18 years of age, reports on the effectiveness and safety of such medications in children and adolescent patients are of importance.

Motivational interviewing for smoking cessation in a psychiatric day hospital: a feasibility study.

OBJECTIVE: Our main objective was to test the feasibility of adding motivational interviewing to the usual smoking cessation treatment for patients with psychiatric disorders attending a day hospital. METHODS: A total of 44 patients participated in the study: a comparison group of 25 patients, all of whom received the usual smoking cessation treatment (nicotine replacement therapy, 1 hour of weekly group therapy, and daily individual advice), and an intervention group of 19 patients who received the usual smoking cessation treatment plus up to four motivational interviewing sessions. Data included sociodemographics, psychiatric diagnosis, cigarette use, and engagement in treatment. Descriptive analyses were conducted, along with logistic regression to test for differences on abstinence and daily smoking rates. RESULTS: All 19 patients offered the motivational interviewing accepted it, and all of them completed at least one session (M = 2.53, SD = 0.234, Range = 1 to 4). At the end of treatment, four patients in the intervention group were abstinent (versus none in the comparison group), but this was not statistically significant. Both groups showed a mean daily reduction of eight cigarettes. After introducing all variables into the regression models, none reached significance. CONCLUSIONS: Adding motivational interviewing to usual smoking cessation treatment in a psychiatric day hospital seems feasible and acceptable. Further, more rigorous research is needed.

Visión de un residente español de la psiquiatría del siglo XXI / A Spanish resident's vision of 21 st century psychiatry

No disponible

Hacia un sistema sanitario absolutamente sostenible / Towards an absolutely supportable health care system

No disponible